Core Viewpoint - The legal opinion letter addresses the adjustments to the grant price, the achievement of vesting conditions for the first grant's third vesting period, and the cancellation of certain restricted stocks related to Hangzhou Aotai Biotechnology Co., Ltd.'s 2022 restricted stock incentive plan [1][4][23] Summary by Relevant Sections Legal Framework and Compliance - The law firm conducted its review based on the Company Law, Securities Law, and relevant regulations, ensuring that all documents provided by the company were authentic, accurate, and complete [2][3][4] - The law firm confirmed that the legal opinions provided are based solely on current Chinese laws and do not extend to any foreign laws [4][5] Incentive Plan Adjustments - The grant price for the incentive plan was adjusted from 51.00 CNY per share to 28.0067 CNY per share, and the number of shares granted was increased from 770,000 to 1,132,516 shares [10][12] - The adjustments were deemed to comply with the relevant regulations and did not harm the interests of the company or its shareholders [10][14] Vesting Conditions - The first grant's third vesting period and the reserved grant's second vesting period have been confirmed to meet the necessary conditions, allowing 94 eligible participants to vest a total of 409,472 shares, while 18 reserved participants can vest 29,418 shares [15][22] - The vesting conditions were verified against the company's performance metrics, which included revenue and product registration targets [21][22] Cancellation of Restricted Stocks - The company plans to cancel a total of 6,177 shares of restricted stock that were granted to three participants who left the company, in accordance with the incentive plan's provisions [22][23] - The cancellation process was confirmed to be compliant with the relevant regulations and did not adversely affect the interests of the company or its shareholders [23]

Core Viewpoint - The report outlines the independent financial advisory opinion regarding the third vesting period and the reserved grant of the second vesting period under the 2022 Restricted Stock Incentive Plan of Hangzhou Aotai Biotechnology Co., Ltd, confirming that the conditions for vesting have been met [1][12][19] Group 1: Incentive Plan Overview - The 2022 Restricted Stock Incentive Plan includes provisions for granting restricted stocks to eligible participants, including directors, senior management, and key technical personnel [1][4] - The first grant date for the restricted stocks was July 22, 2022, with the third vesting period commencing 36 months after this date [12][13] - The total number of restricted stocks eligible for vesting is 438,890 shares, with 409,472 shares from the first grant's third vesting period and 29,418 shares from the reserved grant's second vesting period [12][19] Group 2: Approval Process - The approval process for the incentive plan involved multiple meetings, including the second board meeting on June 27, 2022, where the plan was reviewed and approved [5][6] - The plan was publicly disclosed on the Shanghai Stock Exchange website on June 28, 2022, following the board's approval [6][7] - Subsequent meetings were held to verify the eligibility of the incentive recipients and to approve the reserved grants, with the latest meeting occurring on April 28, 2023 [8][9] Group 3: Vesting Conditions - The vesting conditions for the restricted stocks include the absence of adverse audit opinions and the fulfillment of performance targets related to business revenue and research and development [13][14] - The performance targets set for the first vesting period include achieving a business revenue of at least 6.01 billion yuan and obtaining regulatory approvals for a minimum of 15 self-developed medical device products [17][18] - The report confirms that the conditions for vesting have been satisfied, allowing the eligible participants to receive their shares [12][19]

Core Viewpoint - Aotai Biotech announced an adjustment to the grant price of its 2022 restricted stock incentive plan, reducing it from 25.0725 yuan per share to 23.5992 yuan per share [2] Summary by Relevant Sections - **Company Announcement** - Aotai Biotech held its 14th meeting of the 3rd Board of Directors and the 14th meeting of the 3rd Supervisory Board on August 8, 2025, where the adjustment of the grant price was approved [2] - The adjustment is in accordance with the provisions of the 2022 restricted stock incentive plan draft and the authorization from the first extraordinary general meeting of shareholders in 2022 [2] - **Price Adjustment Details** - The grant price, including the reserved portion, has been adjusted from 25.0725 yuan per share to 23.5992 yuan per share [2]

Group 1 - The board of directors of Hangzhou Aotai Biotechnology Co., Ltd. held its 14th meeting of the third session on August 8, 2025, to discuss and vote on various proposals [1][2] - The board proposed to adjust the grant price of the 2022 Restricted Stock Incentive Plan from 25.0725 yuan per share to 23.5992 yuan per share, with a unanimous vote of 4 in favor [2][3] - The board approved the vesting of restricted stocks for 94 eligible incentive objects, totaling 409,472 shares, and for 18 reserved incentive objects, totaling 29,418 shares, based on the fulfillment of vesting conditions [2][3] Group 2 - The board decided to cancel 6,177 shares of restricted stock that were granted but not vested due to three incentive objects leaving the company [3][5] - All proposals discussed in the meeting were approved with no votes against or abstentions, indicating strong support from the board members [2][3]

Core Points - The Supervisory Board of Hangzhou Aotai Biotechnology Co., Ltd. has reviewed and approved the list of beneficiaries for the third vesting period of the 2022 restricted stock incentive plan and the second vesting period of the reserved grant [1][2] - A total of 94 beneficiaries are proposed for the third vesting period and 18 beneficiaries for the second vesting period, all of whom meet the qualifications set forth in relevant laws and regulations [1][2] Summary by Sections - **Regulatory Compliance**: The incentive plan adheres to the Company Law, Securities Law, and other relevant regulations, confirming the legality and validity of the beneficiaries' qualifications [1] - **Beneficiary Eligibility**: The proposed beneficiaries for both vesting periods fulfill the conditions outlined in the incentive plan draft and are deemed eligible to receive restricted stock [1] - **Approval Process**: The Supervisory Board has formally agreed to the beneficiary list for the incentive plan, indicating a structured approval process [2]

Meeting Overview - The third supervisory board meeting of Hangzhou Aotai Biotechnology Co., Ltd. was held on August 8, 2025, with a legal and valid resolution [1] Adjustment of Stock Incentive Plan - The supervisory board approved the adjustment of the grant price for the 2022 Restricted Stock Incentive Plan, in compliance with relevant laws and regulations, ensuring no harm to the company and all shareholders [2][3] - The voting results for the proposal showed 3 votes in favor, 0 against, and 0 abstentions [2] Vesting Conditions - The vesting conditions for the first grant of the third vesting period and the reserved grant of the second vesting period have been met, allowing 94 eligible incentive recipients to vest a total of 409,472 shares, and 18 reserved recipients to vest 29,418 shares [2][3] - The voting results for this proposal also showed 3 votes in favor, 0 against, and 0 abstentions [3] Cancellation of Stock Grants - Due to the departure of 3 incentive recipients, a total of 6,177 shares of unvested restricted stock will be canceled, in accordance with relevant laws and the 2022 Incentive Plan [3] - The voting results for the cancellation proposal were 3 votes in favor, 0 against, and 0 abstentions [3]

奥泰生物（SH 688606，收盘价：74.15元）8月8日晚间发布公告称，公司第三届第十四次董事会会议于 2025年8月8日在公司会议室以现场与通讯相结合的方式召开。会议审议了《关于的议案》等文件。 2024年1至12月份，奥泰生物的营业收入构成为：体外诊断行业占比99.51%，其他业务占比0.49%。 （文章来源：每日经济新闻） ...

证券代码：688606 证券简称：奥泰生物 公告编号：2025-032 杭州奥泰生物技术股份有限公司 关于作废 2022 年限制性股票激励计划 部分限制性股票的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 杭州奥泰生物技术股份有限公司（以下简称"公司"）于 2025 年 8 月 8 日 召开的第三届董事会第十四次会议和第三届监事会第十四次会议，审议通过了 《关于<作废 2022 年限制性股票激励计划部分限制性股票>的议案》。现将有关 事项说明如下： 一、2022 年限制性股票激励计划已履行的决策程序和信息披露情况 （一）2022 年 6 月 27 日，公司召开第二届董事会第十五次会议，审议通过 了《关于<杭州奥泰生物技术股份有限公司 2022 年限制性股票激励计划（草案） 及其摘要>的议案》《关于<杭州奥泰生物技术股份有限公司 2022 年限制性股票 激励计划实施考核管理办法>的议案》及《关于提请股东大会授权董事会办理公 司 2022 年限制性股票激励计划有关事项的议案》。公司独立董事就本次激励计 划相关议案发表了 ...

证券代码：688606 证券简称：奥泰生物 公告编号：2025-031 杭州奥泰生物技术股份有限公司 关于 2022 年限制性股票激励计划首次授予第三个归 属期及预留授予第二个归属期符合归属条件的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 限制性股票拟归属数量（调整后）：438,890 股。其中，首次授予第三个 归属期拟归属 409,472 股，预留授予第二个归属期拟归属 29,418 股 归属股票来源：公司从二级市场回购的公司 A 股普通股股票 杭州奥泰生物技术股份有限公司（以下简称"公司"）于 2025 年 8 月 8 日 召开的第三届董事会第十四次会议和第三届监事会第十四次会议，审议通过了 《关于<2022 年限制性股票激励计划首次授予第三个归属期及预留授予第二个 归属期符合归属条件>的议案》，公司 2022 年限制性股票激励计划（以下简称"本 次激励计划"）首次授予第三个归属期及预留授予第二个归属期归属条件已经成 就，本次首次授予符合条件的 94 名激励对象可归属的限制性股票数量合计为 4 ...

杭州奥泰生物技术股份有限公司 关于调整 2022 年限制性股票激励计划 授予价格的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示 限制性股票授予价格：由 25.0725 元/股调整为 23.5992 元/股 杭州奥泰生物技术股份有限公司（以下简称"公司"）于 2025 年 8 月 8 日召开的第三届董事会第十四次会议和第三届监事会第十四次会议，审议通过了 《关于<调整 2022 年限制性股票激励计划授予价格>的议案》。根据《杭州奥泰 生物技术股份有限公司 2022 年限制性股票激励计划（草案）》（以下简称"《2022 年激励计划》"）的相关规定及公司 2022 年第一次临时股东大会授权，董事会 对公司 2022 年限制性股票激励计划（以下简称"本次激励计划"）的授予价格 进行调整。授予价格（含预留部分）由 25.0725 元/股调整为 23.5992 元/股。现 将有关事项说明如下： 证券代码：688606 证券简称：奥泰生物 公告编号：2025-030 （五）2022 年 7 月 22 日，公司召开第 ...